Bionomics and Merck & Co. agreed to collaborate in the discovery and development of novel small molecule candidates for treatment of neuropathic pain and other forms of chronic pain using the latter's ionX drug discovery technology and MultiCore chemistry. The deal grants Merck an option for an exclusive license for one compound. Bionomics could get as much as $172 million in option exercise fees and milestone payments plus sales royalties.
Merck, Bionomics team up to develop chronic pain drug
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||